Jossan S S, Adem A, Winblad B, Oreland L
Department of Medical Pharmacology, University of Uppsala, Sweden.
Pharmacol Toxicol. 1992 Sep;71(3 Pt 1):213-5. doi: 10.1111/j.1600-0773.1992.tb00548.x.
The effects of 1,2,3,4-tetrahydro-9-aminoacridine (THA) on uptake rates of radioactive 5-hydroxytryptamine (5-HT) and dopamine were investigated in rat diencephalon and striatal homogenates, respectively. Six and eight microM of THA were needed to inhibit 50% of dopamine and 5-HT uptake rates. Kinetic parameters, Km and Vmax, using six different concentrations of dopamine and 5-HT were estimated in the presence or absence of THA. A significant decrease in Vmax without any change in Km values was observed for both dopamine and 5-HT in the presence of THA. The results show that THA is a non-competitive uptake inhibitor of dopamine and 5-HT in the nerve terminals. The re-uptake blocking effect of THA on dopaminergic and serotonergic neurones, following THA treatment, might lead to increased levels of these monoamines in brains of Alzheimer patients and contribute in the therapeutic effects of the drug.
分别在大鼠间脑和纹状体匀浆中研究了1,2,3,4-四氢-9-氨基吖啶(THA)对放射性5-羟色胺(5-HT)和多巴胺摄取率的影响。抑制50%的多巴胺和5-HT摄取率分别需要6微摩尔和8微摩尔的THA。在有或没有THA的情况下,使用六种不同浓度的多巴胺和5-HT估计动力学参数Km和Vmax。在有THA的情况下,观察到多巴胺和5-HT的Vmax显著降低,而Km值没有任何变化。结果表明,THA是神经末梢中多巴胺和5-HT的非竞争性摄取抑制剂。THA治疗后对多巴胺能和血清素能神经元的再摄取阻断作用,可能会导致阿尔茨海默病患者大脑中这些单胺水平升高,并有助于该药物的治疗效果。